Zn2+ reverses functional deficits in a de novo dopamine transporter variant associated with autism spectrum disorder

Molecular Autism

Volumn 6, Issue 1, 2015, Pages

  Hamilton, Peter J ^a   Shekar, Aparna ^a   Belovich, Andrea N ^a   Christianson, Nicole Bibus ^a   Campbell, Nicholas G ^a   Sutcliffe, James S ^a   Galli, Aurelio ^a   Matthies, Heinrich J G ^a   Erreger, Kevin ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Autism spectrum disorder; De novo mutation; Dopamine; Transporter; Zinc

Indexed keywords

DOPAMINE TRANSPORTER; ZINC ION;

ARTICLE; AUTISM; CURRENT CLAMP TECHNIQUE; DAT GENE; DOPAMINE UPTAKE; DOPAMINERGIC TRANSMISSION; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG TARGETING; FUNCTIONAL DISEASE; GENE FUNCTION; GENE TARGETING; GENETIC VARIABILITY; MOLECULAR BIOLOGY; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; WHOLE CELL PATCH CLAMP;

EID: 84928732481     PISSN: None     EISSN: 20402392     Source Type: Journal    
DOI: 10.1186/s13229-015-0002-7     Document Type: Article

References (12)

1. Kristensen AS, Andersen J, Jorgensen TN, Sorensen L, Eriksen J, Loland CJ, et al. SLC6 neurotransmitter transporters: structure, function, and regulation. Pharmacol Rev. 2011;63(3):585-640. doi:10.1124/pr.108.000869.
2. Norregaard L, Frederiksen D, Nielsen EO, Gether U. Delineation of an endogenous zinc-binding site in the human dopamine transporter. EMBO J. 1998;17(15):4266-73.
3. Loland CJ, Norregaard L, Gether U. Defining proximity relationships in the tertiary structure of the dopamine transporter. Identification of a conserved glutamic acid as a third coordinate in the endogenous Zn(2+)-binding site. J Biol Chem. 1999;274(52):36928-34.
4. Krishnamurthy H, Gouaux E. X-ray structures of Leu T in substrate-free outward-open and apo inward-open states. Nature. 2012;481(7382):469-74. doi:10.1038/nature10737.
5. Hamilton PJ, Campbell NG, Sharma S, Erreger K, Herborg Hansen F, Saunders C, et al. De novo mutation in the dopamine transporter gene associates dopamine dysfunction with autism spectrum disorder. Mol Psychiatry. 2013;18(12):1315-23. doi:10.1038/mp.2013.102.
6. Sulzer D, Sonders MS, Poulsen NW, Galli A. Mechanisms of neurotransmitter release by amphetamines: a review. Prog Neurobiol. 2005;75(6):406-33.
7. Kahlig KM, Lute BJ, Wei Y, Loland CJ, Gether U, Javitch JA, et al. Regulation of dopamine transporter trafficking by intracellular amphetamine. Mol Pharmacol. 2006;70(2):542-8. doi:10.1124/mol.106.023952.
8. Loland CJ, Norregaard L, Litman T, Gether U. Generation of an activating Zn (2+) switch in the dopamine transporter: mutation of an intracellular tyrosine constitutively alters the conformational equilibrium of the transport cycle. Proc Natl Acad Sci U S A. 2002;99(3):1683-8.
9. Stockner T, Montgomery TR, Kudlacek O, Weissensteiner R, Ecker GF, Freissmuth M, et al. Mutational analysis of the high-affinity zinc binding site validates a refined human dopamine transporter homology model. PLoS Comput Biol. 2013;9(2):e1002909. doi:10.1371/journal.pcbi.1002909.
10. Faber S, Zinn GM, Kern 2nd JC, Kingston HM. The plasma zinc/serum copper ratio as a biomarker in children with autism spectrum disorders. Biomarkers. 2009;14(3):171-80. doi:10.1080/13547500902783747.
11. Jackson MJ, Garrod PJ. Plasma zinc, copper, and amino acid levels in the blood of autistic children. J Autism Child Schizophr. 1978;8(2):203-8.
12. Li SO, Wang JL, Bjorklund G, Zhao WN, Yin CH. Serum copper and zinc levels in individuals with autism spectrum disorders. Neuroreport. 2014;25 (15):1216-20. doi:10.1097/WNR.0000000000000251.